Oxidative ipso substitution of 2,4-difluoro-benzylphthalazines: Identification of a rare stable quinone methide and subsequent GSH conjugate

Drug Metabolism and Disposition

Volumn 40, Issue 11, 2012, Pages 2074-2080

  Gunduz, Mithat ^a   Argikar, Upendra A ^a   Kamel, Amin ^a   Colizza, Kevin ^a   Bushee, Jennifer L ^a   Cirello, Amanda ^a   Lombardo, Franco ^a   Harriman, Shawn ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[2 [6 [4 [4 (2,4 DIFLUOROBENZYL)PHTHALAZIN 1 YL]PIPERAZIN 1 YL]PYRIDIN 3 YL]PROPAN 2 OL]; BENZENE DERIVATIVE; CARBENE; CYTOCHROME P450; CYTOCHROME P450 3A4; FLUORINE; GLUTATHIONE; PHTHALAZINE DERIVATIVE; QUINONE DERIVATIVE; QUINONE METHIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOTRANSFORMATION; CATALYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; LIVER MICROSOME; METABOLITE; OXIDATION; PHENOTYPE; PRIORITY JOURNAL; SUBSTITUTION REACTION;

BENZYL COMPOUNDS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; GLUTATHIONE; HEDGEHOG PROTEINS; HUMANS; INDOLEQUINONES; MICROSOMES, LIVER; NADP; OXIDATION-REDUCTION; PHTHALAZINES; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84867682049     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.046268     Document Type: Article

References (29)

1. Argikar UA, Mangold JB, and Harriman SP (2011) Strategies and chemical design approaches to reduce the potential for formation of reactive metabolic species. Curr Top Med Chem 11:419-449.
2. Bolton JL, Acay NM, and Vukomanovic V (1994) Evidence that 4-allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem Res Toxicol 7:443-450. (Pubitemid 24150107)
3. Bolton JL, Sevestre H, Ibe BO, and Thompson JA (1990) Formation and reactivity of alternative quinone methides from butylated hydroxytoluene: possible explanation for species-specific pneumotoxicity. Chem Res Toxicol 3:65-70. (Pubitemid 20128631)
4. Bolton JL and Thompson JA (1991) Oxidation of butylated hydroxytoluene to toxic metabolites. Factors influencing hydroxylation and quinone methide formation by hepatic and pulmonary microsomes. Drug Metab Dispos 19:467-472.
5. Damsten MC, de Vlieger JS, Niessen WM, Irth H, Vermeulen NP, and Commandeur JN (2008) Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s. Chem Res Toxicol 21:2181-2187.
6. Driscoll JP, Kornecki K, Wolkowski JP, Chupak L, Kalgutkar AS, and O'Donnell JP (2007) Bioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate. Chem Res Toxicol 20:1488-1497. (Pubitemid 350057218)
7. Fan PW and Bolton JL (2001) Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab Dispos 29:891-896. (Pubitemid 32488647)
8. Fan PW, Zhang F, and Bolton JL (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem Res Toxicol 13:45-52. (Pubitemid 30055958)
9. Iverson SL, Hu LQ, Vukomanovic V, and Bolton JL (1995) The influence of the p-alkyl substituent on the isomerization of o-quinones to p-quinone methides: potential bioactivation mechanism for catechols. Chem Res Toxicol 8:537-544.
10. Iverson SL, Shen L, Anlar N, and Bolton JL (1996) Bioactivation of estrone and its catechol metabolites to quinoid-glutathione conjugates in rat liver microsomes. Chem Res Toxicol 9:492-499.
11. Kalgutkar AS, Driscoll J, Zhao SX, Walker GS, Shepard RM, Soglia JR, Atherton J, Yu L, Mutlib AE, Munchhof MJ, et al. (2007) A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif. Chem Res Toxicol 20:1954-1965.
12. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, et al. (2005a) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225. (Pubitemid 40753853)
13. Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, et al. (2005b) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243-253. (Pubitemid 40216592)
14. Kiesslich T and Neureiter D (2012) Advances in targeting the Hedgehog signaling pathway in cancer therapy. Expert Opin Ther Targets 16:151-156.
15. Liu J, Liu H, van Breemen RB, Thatcher GR, and Bolton JL (2005) Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol 18:174-182. (Pubitemid 40256235)
16. Miller-Moslin K, Peukert S, Jain RK, McEwan MA, Karki R, Llamas L, Yusuff N, He F, Li Y, Sun Y, et al. (2009) 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem 52:3954-3968.
17. Nüsslein-Volhard C and Wieschaus E (1980) Mutations affecting segment number and polarity in Drosophila. Nature 287:795-801. (Pubitemid 11214475)
18. Peukert S and Miller-Moslin K (2010) Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 5:500-512.
19. Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, Amsellem-Ouazana D, and Bieche I (2012) Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer 106:1177-1186.
20. Raju GP and Pham D (2012) Hedgehog inhibition as an anti-cancer strategy. Vitam Horm 88:507-522.
21. Steenwyk RC and Tan B (2010) In vitro evidence for the formation of reactive intermediates of resveratrol in human liver microsomes. Xenobiotica 40:62-71.
22. Tajima K, Yamamoto K, and Mizutani T (1985) Formation of a glutathione conjugate from butylated hydroxytoluene by rat liver microsomes. Biochem Pharmacol 34:2109-2114. (Pubitemid 15017070)
23. Thompson D, Constantin-Teodosiu D, Egestad B, Mickos H, and Molde'us P (1990) Formation of glutathione conjugates during oxidation of eugenol by microsomal fractions of rat liver and lung. Biochem Pharmacol 39:1587-1595. (Pubitemid 20157846)
24. Wen B, Chen Y, and Fitch WL (2009) Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4. Drug Metab Dispos 37:1557-1562.
25. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF 2nd, Schroeder MC, Kunze KL, and Trager WF (1993) Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos 21:874-882. (Pubitemid 23298455)
26. Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, and Huebert N (2005) Bioactivation of 4-methylphenol (p-cresol) via cytochrome P450-mediated aromatic oxidation in human liver microsomes. Drug Metab Dispos 33:1867-1876. (Pubitemid 41697273)
27. Yang L, Su X, and Xie J (2012) Activation of Hedgehog pathway in gastrointestinal cancers. Vitam Horm 88:461-472.
28. Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, Zhu M, Rinehart JK, Klunk L, and Mitroka J (2003) Protein covalent binding of maxipost through a cytochrome P450-mediated orthoquinone methide intermediate in rats. Drug Metab Dispos 31:837-845. (Pubitemid 36759052)
29. Zhang F, Chen Y, Pisha E, Shen L, Xiong Y, van Breemen RB, and Bolton JL (1999) The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem Res Toxicol 12:204-213. (Pubitemid 29096070)